CSL Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CSLLY research report →
About the company
CSL Limited is a global biopharmaceutical enterprise dedicated to the research, development, production, marketing, and distribution of a wide array of biopharmaceutical and related healthcare products. The company boasts a significant international presence, with operations spanning major markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China, alongside other territories worldwide. Its business is primarily structured around two key divisions: CSL Behring and Seqirus.
- CEO
- Gordon Naylor DipCompSc
- IPO
- 2009
- Employees
- 32,698
- HQ
- Melbourne, VIC, AU
Price Chart
- Market Cap
- $79.34B
- P/E
- 28.38
- P/S
- 2.58
- P/B
- 2.19
- EV/EBITDA
- 10.09
- Div Yield
- 3.50%
- Gross Margin
- 48.64%
- Op Margin
- 25.72%
- Net Margin
- 9.17%
- ROE
- 7.56%
- ROIC
- 10.37%
- Revenue
- $15.43B · 4.26%
- Net Income
- $3.00B · 13.63%
- EPS
- $0.39 · 13.35%
- Op Income
- $2.96B
- FCF YoY
- 68.92%
- 52W High
- $44.85
- 52W Low
- $16.01
- 50D MA
- $19.40
- 200D MA
- $26.72
- Beta
- 0.09
- Avg Volume
- 502.38K
Get TickerSpark's AI analysis on CSLLY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our CSLLY coverage
Recent articles, reports, and earnings notes.
No research on CSLLY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CSLLY report →Similar companies
Peers in the same neighborhood.